Background: Melanoma of unknown primary (MUP) is incompletely described on a population level.
M elanoma of unknown primary (MUP) refers to melanoma presenting without an identifiable primary site and accounts for approximately 3.2% of all melanoma diagnoses. 1, 2 The American Joint Committee on Cancer classifies MUP as stage III disease if it is initially diagnosed within a lymph node or subcutaneous tissue and as stage IV disease if it is initially diagnosed within a visceral organ. 3 Stage IV MUP comprises only 5% of all MUP cases, and the majority of studies investigating stage IV MUP describe relatively small patient cohorts derived from single institutions. 4, 5 In fact, a recent systematic review and meta-analysis of MUP revealed only 6 studies of stage IV MUP comprising more than 10 patients, and only 1 study from the Netherlands was population based. [4] [5] [6] [7] [8] [9] [10] As such, the specific prognostic factors for stage IV MUP are not clear.
MUP is often attributed to primary tumor regression mediated through immunologic mechanisms. 11, 12 Interestingly, 2 systematic reviews of institutional MUP cohorts revealed that patients with MUP have improved survival when compared with patients with stage-matched melanoma of known primary (MKP). 2, 5 The favorable prognosis of MUP is hypothesized to arise from enhanced antitumor immune responses, as MKP tumors enriched for a gene signature associated with lymphocyte infiltration are associated with improved survival. 13, 14 Moreover, age and sex may affect antitumor immune responses and therefore may play a critical role in the prognosis of MUP. [15] [16] [17] Although age and sex affect the survival of MKP, there is currently no consensus on the effect of age or sex on prognosis specifically for stage IV MUP. 2, 5, 15, 18, 19 To better characterize stage IV MUP on a population level, we developed a novel search algorithm for identifying cases of stage IV MUP from the Surveillance, Epidemiology, and End Results (SEER) 18 registries. Our objective was to determine the age-standardized incidence rates, demographic characteristics, survival, and prognostic factors for stage IV MUP in a large population-based cancer registry and to compare them with the rates, characteristics, and factors for stage IV MKP.
MATERIALS AND METHODS

Stage IV MUP case selection
We identified cases of stage IV MUP and stage IV MKP diagnosed between 1973 and 2014 in the SEER 18 registries (November 2016 submission), which capture approximately 28% of the US population. 20 SEER records primary malignancies but not metastatic sites. Cases with histologic confirmation of primary malignant melanoma diagnosed in a visceral site were classified as stage IV MUP (for the search algorithm, see the Supplemental Methods; available at http://www.jaad.org). We assumed that melanoma diagnosed in a visceral primary site represented either a true case of MUP or, alternatively, a case of MKP in which the visceral site of metastatic disease was miscoded as a primary site. To address the latter possibility, we excluded cases with MKP diagnosed either before (n = 37), simultaneously with (n = 4), or after (n = 10) the visceral site diagnosis. Moreover, MUP cases with histologic subtypes suggestive of a known primary (superficial spreading melanoma [n = 1], lentigo maligna melanoma [n = 1], and mucosal lentiginous melanoma [n = 1]) and MUP cases specifically coded with a nonmetastatic disease stage (American Joint Committee on Cancer M0
stage coding [n = 38]) were also excluded given the potential for misclassification. Finally, cases with incomplete follow-up (n = 61) and cases diagnosed by death certificate only (n = 2) were excluded. Cases with incomplete follow-up were defined as those without complete dates available for months of survival. MUP sites were broadly classified as gastrointestinal tract, central nervous system, respiratory tract, parotid gland, unknown primary site, and other specified site.
Stage IV MKP case selection
We next identified a comparison group of stage IV MKP cases with histologic confirmation of primary malignant melanoma diagnosed in a known primary site (see the Supplementary Methods for the search algorithm). Cases with a primary tumor that was not malignant melanoma (n = 342) and cases with incomplete follow-up (n = 1857) were excluded. Stage IV MKP cases were classified as stage IV cutaneous (n = 11,863), mucosal (n = 745), or ocular (n = 188) melanoma.
Statistical analysis
Data extracted from the SEER registries included year of diagnosis, age, sex, race, histology, primary site, surgical treatment, follow-up time, and cause of death. Year of diagnosis was categorized into decades, including 1973 to 1984, 1985 to 1994, 1995 Stage IV melanoma of unknown primary and known primary share similar diseasespecific survival and negative prognostic factors, including advanced age and lack of surgical treatment.
The number of stage IV MUP cases as a percentage of all stage IV melanoma cases was calculated. Age-standardized incidence rates of stage IV MUP and stage IV MKP were calculated for the aforementioned age categories. 21, 22 Year of diagnosis, age, sex, race, histology, and surgical treatment were compared between stage IV MUP and MKP cases. Descriptive analyses were performed by using the Student t test for continuous variables and the chi-square for categoric variables. Univariate and multivariate Cox proportional hazard models were performed to generate hazard ratios (HRs) and 95% confidence intervals (CIs) for stage IV MUP and MKP cases.
Disease-specific survival (DSS) was calculated as the number of months following the diagnosis of stage IV disease, with death being defined as death from melanoma. Patients who were alive or dead from causes other than melanoma at the end of the follow-up period were censored as living. First, relative survival, which compares the survival of patients with cancer with that of the general US population and adjusts for age, sex, and race, was calculated for stage IV MUP and MKP. 23 Next, adjusted DSS Kaplan-Meier curves were generated for stage IV MUP and stage IV MKP, controlling for year of diagnosis, age, sex, race, and surgical treatment. Finally, adjusted DSS Kaplan-Meier curves were generated for stage IV MUP stratified by year of diagnosis. The Kaplan-Meier method was used to estimate differences in adjusted DSS between groups, and the log-rank test was performed to determine statistical significance.
RESULTS
A total of 322 stage IV MUP and 12,796 stage IV MKP cases were identified in the SEER 18 registries in the period from 1973 to 2014 (Fig 1) . MUP cases presented most often in the gastrointestinal tract (45.0%), followed by the central nervous system (11.0%), respiratory tract (8.7%), and parotid gland (6.8%). The primary site was coded as unknown in 22.0% of cases. Stage IV MUP comprised 2.5% of all stage IV melanoma diagnoses. The incidence of stage IV MUP increased from 1.52 per 100,000 patients in the decade from 1973 to 1984 to 5.83 per 100,000 patients in the decade from 2005 to 2014, and the rate of increase was greatest for patients younger than 30 years of age (Tables I and II) . Overall, the age-standardized incidence rate was also highest for patients who had stage IV MUP and were younger than 30 years of age in the decade from 2005 to 2014 (3.32 per 100,000).
The descriptive characteristics of stage IV MUP and MKP cases are presented in Table III . Stage IV MUP and MKP cases were overall similar demographically. However, surgery was more likely to be recommended and performed in stage IV MUP cases than in stage IV MKP cases (P = .001). (Fig 2, A) . However, there were no differences in DSS between stage IV MUP and MKP in the multivariate Cox proportional hazard models (HR, 0.91; 95% CI, 0.79-1.04; P = .16) or the 5-year DSS Kaplan-Meier curve adjusting for year of diagnosis, age, sex, race, and surgical treatment (log-rank P = .93 [ Fig 2, B] ). Moreover, there was no statistically significant difference between the 5-year adjusted DSS Kaplan-Meier curves for stage IV MUP and those for stage IV cutaneous, mucosal, or ocular melanoma (log-rank P = .54 [ Supplemental Fig 1; (Table IV) 
DISCUSSION
This study characterizes patients with stage IV MUP on a population level by using a large national cancer registry, and it represents the first such study performed in the United States. We developed a novel search algorithm for identifying stage IV MUP cases within the SEER registries. Stage IV MUP comprised 2.5% of all stage IV melanoma diagnoses, which is comparable to the percentages reported in 2 systematic reviews of MUP (3.2% and 2.3%, respectively).
2,5 Moreover, the stage IV MUP cases in the SEER registries were similar to cases of MUP previously reported in the literature from single institutions, including in terms of being characterized by a predominance of male sex and white race, mean age of diagnosis in the fifth decade of life, and the most common presentation involving the gastrointestinal tract. 2, 5, 24 Finally, the median survival time and 1-year and 5-year overall survival rates for stage IV MUP in the SEER registries were similar to those reported in the literature for stage IV MUP (8.0 months versus 9.9 months, 41.0% versus Collectively, these data support the validity of this novel search algorithm for accurately identifying stage IV MUP cases within the SEER registries. Compared with nodal presentations, visceral presentations of MUP are less well characterized. Our results clarify the age-standardized incidence rates, prognostic factors, and survival of stage IV MUP. First, similar to the incidence of stage IV MKP, the incidence of stage IV MUP has been increasing since 1973 and is highest for patients younger than 30 years. Second, our results support prior studies of MUP and suggest a poorer prognosis for older adults. Although the impact of sex on prognosis could not be conclusively determined in our study, it is possible that with increasing sample size the trend for a poorer prognosis in males would reach statistical significance in a similar fashion as stage IV MKP. Third, although relative survival of stage IV MUP was better than that of stage IV MKP, DSS was equivalent between the 2 groups. This discrepancy may be due to the fact that relative survival measures the proportion of deaths in the cancer group compared with that in an equivalent cancer-free group, whereas DSS relies on accurately deciding whether each death was wholly attributed to the cancer of interest. 25 In addition, the stage IV MUP cohort was small, with limited patients for each set of confounders. Finally, the biologic and prognostic heterogeneity of melanoma is increasingly being recognized, with the genetic profile of MUP most closely resembling that of cutaneous melanoma. [26] [27] [28] Yet, the prognosis of MUP compared with that of mucosal and ocular melanoma is unknown. Our study clarifies the prognosis of stage IV MUP, demonstrating similar DSS between stage IV MUP and stage IV mucosal and ocular melanoma.
Various theories have been proposed to explain MUP, including spontaneous primary tumor regression from immune surveillance. 12, 29, 30 Younger age is associated with a more robust immune response to cancer vaccines, and sex differences in immune function, possibly related to hormonal influences, are hypothesized to contribute to the survival advantage of females with melanoma. [15] [16] [17] Further investigation is warranted to determine whether the negative prognostic impact of advancing age and possibly male sex may be related to differences in antitumor immune responses in patients with MUP. Similarly, the higher incidence of stage IV MUP in patients younger than 30 may be related to an increased likelihood for spontaneous primary tumor regression. Interestingly, after control for important confounding variables, patients with stage IV MUP were more likely than patients with stage IV MKP to be offered surgical treatment. This may be explained by the fact that patients with worse prognoses were not offered surgical treatment. Another plausible interpretation of this finding is that stage IV MUP presents more commonly with solitary visceral metastases or oligometastatic disease, which may be more amenable to surgical intervention. The burden of metastatic disease at presentation for patients with stage IV MUP and MKP and how it relates to surgical treatment recommendations deserve additional study, as this may partially explain the favorable prognosis of patients with MUP. For example, a variety of surgical treatments, including radical node dissection, modified radical neck dissection, and metastasectomy, are all associated with better outcomes for patients with stage IV MUP. 5, [31] [32] [33] There are a number of important limitations of this study. MKP is commonly misclassified as MUP in clinical practice, with the misclassification most often resulting from an incomplete medical history or physical examination. As such, identifying MUP cases from a large population-based cancer registry is particularly challenging given the potential for misclassification of MKP as MUP. We anticipated the possibility of visceral metastases from MKP being miscoded as a second unique primary site within the SEER registries. Thus, we excluded cases with a primary melanoma diagnosed before, simultaneously with, or after the diagnosis of stage IV MUP. Additionally, the percentage of stage IV MUP cases in this study is strongly influenced by the large number of stage IV MKP cases. In fact, including all stage IV MUP cases identified from the original search strategy without excluding any cases (n = 477) yields a similar overall percentage of stage IV MUP cases (3.6%). The rationale for further excluding cases as described earlier in this article was to remove additional sources of misclassification and ultimately generate a more homogeneous stage IV MUP cohort.
In addition to the potential misclassification of MKP as MUP, information regarding the specific type of surgical treatment was not extracted from the SEER registries, and the type of surgical treatment offered could act as confounding variable influencing prognosis. Similarly, nonsurgical treatments, including chemotherapy and radiation therapy, were not included in our models, as they are not readily available within the SEER data submission utilized for this study. Finally, we were not able to analyze cases of stage III MUP because of limitations with the coding of lymph node and subcutaneous primary sites within the SEER registries. As such, cases of stage III MUP may have been misclassified as stage IV MUP.
In conclusion, we have presented a novel search algorithm for accurately identifying stage IV MUP cases within the SEER registries, which allowed for the characterization of stage IV MUP in a large population-based cancer registry over the past 4 decades. Notably, the age-standardized incidence rates and prognostic factors for stage IV MUP were clarified, with patients older than 50 years of age and those not being offered surgical treatment having a worse prognosis. The improved prognosis of younger patients with stage IV MUP may be related to inherent differences in immune function that drive systemic antitumor responses analogous to the favorable clinical responses observed following traditional immunotherapy for melanoma. 
SUPPLEMENTAL METHODS
Stage IV melanoma of unknown primary search algorithm We used a case listing session to identify stage IV melanoma of unknown primary cases, with the following selection algorithm: International Classification of Diseases for Oncology, Third Edition, histology codes for melanoma (nevi and melanomas: 8720-8799, excluding in situ cases) and primary site codes, including the gastrointestinal tract extending from the esophagus to the sigmoid colon (C15.0-C18.9 and C26.0-C26.9), liver (C22.0), gallbladder (C23.9), biliary tract (C22.1 and C24.0-C24.9), pancreas (C25.0-C25.9), trachea (C33.9), lungs (C34.0-C34.9), thymus (C37.9), heart (C38.0), mediastinum (C38.1-C38.8), bones (C40.0-C41.9), bone marrow (C42.2), reticuloendothelial and hematopoietic systems (C42.0-C42.4), uterine adnexa and ovaries (C56.9-C57.9), testes (C62.0-C63.1), prostate gland (C61.9), kidney (C64.9), brain and central nervous system excluding the meninges (C71.0-C72.9), thyroid gland (C73.9), adrenal gland (C74.0-C74.9), parotid gland (C07.9), and unknown primary site (C80.9).
Stage IV melanoma of known primary search algorithm
We used a case listing session to identify stage IV melanoma of known primary cases, with the following selection algorithm: International Supplemental Fig 1. Five-year disease-specific survival Kaplan-Meier curves for stage IV melanoma of unknown primary and stage IV cutaneous, mucosal, and ocular melanoma adjusted for age, sex, race, and surgical treatment.
Supplemental Fig 2.
Five-year disease-specific survival Kaplan-Meier curves for year of diagnosis of stage IV melanoma of known primary (MKP) (A) and stage IV melanoma of unknown primary (MUP) adjusted for age, sex, race, and surgical treatment (B). 
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